October 5, 2017 08:22 AM EDT
R&D

Aca­dia adopts a new PhI­II game plan for 'break­through' med, dumps Alzheimer's PhII

John Carroll

Editor & Founder

Aca­dia $ACAD has de­cid­ed to change the game for its drug Nu­plazid (pi­ma­vanserin) go­ing fur­ther in­to Phase III, af­ter the FDA hand­ed out its break­through …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Rhythm re­ceives ex­pand­ed ap­proval for ge­net­ic obe­si­ty drug

A service from the Financial Times